A detailed history of Gsa Capital Partners LLP transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Gsa Capital Partners LLP holds 67,096 shares of ACAD stock, worth $1.15 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares
67,096
Previous 180,700 62.87%
Holding current value
$1.15 Million
Previous $2.94 Million 64.85%
% of portfolio
0.08%
Previous 0.21%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

SELL
$15.14 - $19.14 $1.72 Million - $2.17 Million
-113,604 Reduced 62.87%
67,096 $1.03 Million
Q2 2024

Aug 15, 2024

BUY
$14.62 - $18.42 $1.01 Million - $1.28 Million
69,306 Added 62.22%
180,700 $2.94 Million
Q1 2024

May 03, 2024

BUY
$17.79 - $30.86 $1.74 Million - $3.02 Million
97,987 Added 730.86%
111,394 $2.06 Million
Q4 2023

Feb 16, 2024

SELL
$20.78 - $31.77 $1.38 Million - $2.11 Million
-66,442 Reduced 83.21%
13,407 $419,000
Q3 2023

Nov 15, 2023

BUY
$20.84 - $33.47 $1.19 Million - $1.91 Million
57,119 Added 251.29%
79,849 $1.66 Million
Q2 2023

Aug 14, 2023

BUY
$17.8 - $25.65 $404,594 - $583,024
22,730 New
22,730 $544,000
Q2 2022

Aug 09, 2022

BUY
$13.01 - $27.22 $396,115 - $828,767
30,447 New
30,447 $429,000
Q4 2021

Feb 14, 2022

SELL
$16.79 - $27.09 $1.15 Million - $1.85 Million
-68,330 Closed
0 $0
Q3 2021

Nov 12, 2021

BUY
$15.78 - $24.77 $1.08 Million - $1.69 Million
68,330 New
68,330 $1.14 Million
Q1 2020

May 12, 2020

SELL
$31.65 - $46.87 $300,231 - $444,608
-9,486 Closed
0 $0
Q4 2019

Feb 12, 2020

SELL
$36.21 - $51.4 $41,713 - $59,212
-1,152 Reduced 10.83%
9,486 $406,000
Q3 2019

Nov 12, 2019

BUY
$22.22 - $44.01 $236,376 - $468,178
10,638 New
10,638 $383,000
Q4 2018

Feb 12, 2019

SELL
$14.32 - $22.92 $167,787 - $268,553
-11,717 Closed
0 $0
Q3 2018

Nov 13, 2018

BUY
$13.03 - $21.81 $152,672 - $255,547
11,717 New
11,717 $243,000

Others Institutions Holding ACAD

About ACADIA PHARMACEUTICALS INC


  • Ticker ACAD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 161,843,008
  • Market Cap $2.76B
  • Description
  • ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...
More about ACAD
Track This Portfolio

Track Gsa Capital Partners LLP Portfolio

Follow Gsa Capital Partners LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Gsa Capital Partners LLP with notifications on news.